期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

达比加群临床疗效与安全性评价 被引量：5

Evaluation of Curative Effect and Safety of Dabigatran
下载PDF
导出
摘要 达比加群作为新型口服抗凝药,近年已被众多指南推荐为防治血栓栓塞性疾病或心房颤动且具有脑卒中风险的一线药物。相对于华法林,达比加群在临床疗效、患者依从性及安全性等方面具有更多优势。现就达比加群的临床疗效及安全性等方面的新近报道进行综述。 The new oral anticoagulant dabigatran has been recommended as a first-line drug by many guidelines for the prevention and treatment of thromboembolic disorders or atrial fibrillation with high risk of stroke. Compared with warfarin,dabigatran has more advantages in clinical curative effect,and patient compliance and safety. The newly published efficacy and safety of dabigatran has been reviewed in this article.
作者 刘维潮 陈化
机构地区 中南大学湘雅二医院
出处 《心血管病学进展》 CAS 2014年第5期581-586,共6页 Advances in Cardiovascular Diseases
基金 湖南省科技厅一般项目资助(2009JT304)
关键词 达比加群 临床疗效 安全性 dabigatran clinical curative effect safety
分类号 R743.3 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献32

  • 1Nancy M, Albert. Use of novel oral anticoagulants for patients with atrial fibrillation: systematic review and clinical implications[J]. Heart Lung, 2014,43 (I) :48-59.
  • 2Connolly SJ , Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N EnglJ Med,2009,361(12) : 1139-115l.
  • 3StangierJ. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate[J]. Clin Pharmacokinet, 2008 ,47 ( 5 ) : 285-295.
  • 4Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)[J].J Am Coli Cardiol,2014 ,63 (4) : 321-328.
  • 5SlangierJ, Rathgen K, Sta H, et al. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate[J]. Clln Pharmacokinet,2010, 49 (4) : 259-268.
  • 6Liesenfeld KH, Lehr T, Dansirikul C, et al. Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non-valvular atrial fibrillation from the RE-LY trial[J]. Thromb Haemost,2011,9( 11) : 2168-2175.
  • 7Pare G, Eriksson N, Lehr T, et al. Genetic determinants of dabigatran plasma levels and their relation to bleeding[J]. Circulation, 2013,127 ( 13): 1404- 1412.
  • 8Hapgood G, ButlerJ, Malan E, et al. The effect of dabigatran on the activated partial thromboplastin time and thrombin time as determined by the Hemoclot thrombin inhibitor assay in patient plasma samples[J]. Thromb Haemost, 2013 , 110(2): 308-315.
  • 9Nagamoto Y, Shiomi T, Matsuura T, et al. Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran[J]. Heart Vessel,2014,29 (4) :560-562.
  • 10Kaku B. Intra-cardiac thrombus resolution after anti-coagulation therapy with dabigatran in a patient with mid-ventricular obstructive hypertrophic cardiomyop- athy , a case report[J].J Med Case Rep, 20 13, 7 (1 ) : 238.

同被引文献66

  • 1周自强,胡大一,陈捷,张仁汉,李奎宝,赵秀丽.中国心房颤动现状的流行病学研究[J].中华内科杂志,2004,43(7):491-494. 被引量：1402
  • 2刁明强,董力,江虹,周静,肖锡俊,张尔永.心脏机械瓣膜置换术后早期抗凝的方法分析[J].中国胸心血管外科临床杂志,2006,13(1):10-13. 被引量：23
  • 3Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of an- ticoagulation with warfarin to prevent stroke in medicare benefici- aries with nonvalvular atrial fibrillation [ J ]. Stroke ,2011,42 (1) : 112-118.
  • 4Bemstein RA, Passman R. Prevention of stroke in patients with high-risk atrial fibrillation [ J ]. Curr Neurol Neurosci Rep, 2010, 10( 1 ) :34-39.
  • 5Camm A J, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibr/llation : an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the Europe- an Heart Rhythm Assoeiation[ J]. Europace, 2012, 14 (10) : 1385-1413.
  • 6Ezekowitz MD, Levine JA. Preventing stroke in patients with atrial fibirillation [ J]. JAMA, 1999,281 ( 19 ) : 1830-1835.
  • 7Whitlock PR,Sun JC ,Fremes SE,et al. Antithrombotic and thromlx~ lytie therapy for valvular disease:Antithrombotic Therapy and pre- vention of Thromlx~is,9thed:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [ J ]. Chest,2012,141 (2 Suppl) :e576s-600s.
  • 8Wang L;MeLeod HL, Weinshilboum RM. Genomics and drug re- spanse[ J]. N Engl J Med,2011,364 (12) :1144-1153.
  • 9Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus war- farin in patients with atrial fibrillation [ J ]. N Engl J Med, 2009, 361 (12) :1139-1151.
  • 10杨帆,张黎军,蒋小波.达比加群220mg和150mg对膝、髋关节置换术后静脉血栓预防的疗效及安全性评价[J].中华临床医师杂志:电子版,2013,7(1):226-232.

引证文献5

二级引证文献32

心血管病学进展
2014年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部